US drugstore chain CVS to buy medical insurer Aetna for $69 billion

December 4, 2017

US drugstore chain CVS Health announced Sunday it would buy medical insurer Aetna for about $69 billion, in a move that would create a new giant in the healthcare sector.

The deal would see Aetna shareholders receive $207 per share, with $145 in cash and the rest in newly issued stock. The overall cost of the transaction rises to $77 billion with the assumption of Aetna's debt.

"The transaction is expected to close in the second half of 2018," CVS said in a statement, adding: "It is subject to approval by CVS Health and Aetna shareholders, regulatory approvals and other customary closing conditions."

Talks between the two have been reported since late October, and are believed to have been driven by rumors of online shopping behemoth Amazon's entry into the drugstore market.

The merger between CVS and Aetna comes amid rising medical for many citizens and employers, including prescription medicines.

The healthcare industry, meanwhile, is preparing for possible cuts to government-funded programs such as Medicaid as a result of Republican tax cuts.

"Today, increasing numbers of consumers are taking on more and more responsibility for paying for their health care as the burden of costs is being shifted to them," the statement said, adding that by merging, the company would be better placed to help customers manage their costs.

"With the analytics of Aetna and CVS Health's human touch, we will create a care platform built around individuals," said CVS Health President and Chief Executive Officer Larry J. Merlo.

Aetna in February announced it had given up its effort to buy rival Humana following 19 months of negotiations, due to opposition by the US Department of Justice which said it would stifle competition.

The acquisition would be considered a so-called "vertical merger" because the companies operate in non-competing industries.

Such deals are usually not opposed by the US government but the Department of Justice last month sued to block a merger between telecommunications giant AT&T and entertainment conglomerate Time Warner.

Explore further: Aetna, Humana call off $34 billion deal

Related Stories

Aetna, Humana call off $34 billion deal

February 14, 2017
Major health insurers Aetna and Humana called off their $34 billion combination after a federal judge, citing concerns about prices and benefits, rejected the deal.

Federal judge swats Aetna-Humana insurer combo

January 23, 2017
A federal judge has rejected health insurer Aetna's bid to buy rival Humana on grounds that the deal would hurt competition in hundreds of Medicare Advantage markets, ultimately affecting the price consumers pay for coverage.

Aetna picks Gilead Sciences hepatitis C drugs over AbbVie's

January 16, 2015
Insurer Aetna has made new hepatitis C drugs from Gilead Sciences Inc. preferred treatments for customers with the liver-destroying virus.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.